Published in Neurosci Lett on March 14, 1994
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57
Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr (2004) 1.53
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics (2006) 1.16
Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis (2009) 1.11
Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem (2014) 1.00
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95
Catalytic antioxidants and neurodegeneration. Antioxid Redox Signal (2009) 0.93
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci (2010) 0.88
Iron-dependent functions of mitochondria--relation to neurodegeneration. J Neural Transm (Vienna) (2010) 0.88
Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network. FEBS Open Bio (2014) 0.88
PGC-1α Promoter Methylation in Parkinson's Disease. PLoS One (2015) 0.85
Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr (1997) 0.80
Both creatine and its product phosphocreatine reduce oxidative stress and afford neuroprotection in an in vitro Parkinson's model. ASN Neuro (2014) 0.78
Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson's Disease. PLoS One (2016) 0.75
Insights into the post-transcriptional regulation of the mitochondrial electron transport chain. Biochem Soc Trans (2016) 0.75
Nuclear and mitochondrial genetics in Parkinson's disease. J Med Genet (1995) 0.75
Parkinson's Disease-Associated Pathogenic VPS35 Mutation Causes Complex I Deficits. Biochim Biophys Acta (2017) 0.75
Sequence analysis of two nuclear encoded subunits (10 and 51 kDa) of mitochondrial complex I in Parkinson disease. Neurogenetics (2002) 0.75
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice. J Endocrinol (2002) 1.94
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (1971) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Design of a Second Generation Firewire Based Data Acquisition System for Small Animal PET Scanners. IEEE Nucl Sci Symp Conf Rec (1997) (2008) 1.77
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant (2010) 1.74
Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med (1996) 1.74
VACTERL with the mitochondrial np 3243 point mutation. Am J Med Genet (1996) 1.72
Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol (1999) 1.71
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J (2004) 1.69
The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol (1991) 1.69
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res (2001) 1.62
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol A Biol Sci Med Sci (2001) 1.59
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry (1996) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
Prevalence of smell loss in Parkinson's disease--a multicenter study. Parkinsonism Relat Disord (2009) 1.50
No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol (2000) 1.49
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Vascular malformations of the central nervous system: a morphological overview. Neurosurg Rev (1986) 1.45
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (1998) 1.45
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 1.44
[Neuroaxonal dystrophies]. Verh Dtsch Ges Pathol (1968) 1.40
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (1995) 1.40
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses. Eur J Neurol (2003) 1.39
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Evolution of the Design of a Second Generation FireWire Based Data Acquisition System. IEEE Nucl Sci Symp Conf Rec (1997) (2010) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol (2011) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Primary intracranial sarcomas: histopathological features of 19 cases. Histopathology (1991) 1.34
Atraumatic needle reduces the incidence of post-lumbar puncture syndrome. J Neurol (1994) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33